S02_RFQ amendment_MSPV Q4 FY26 Open Market_36C24E26Q0058 0001.pdf

5. PROJECT NUMBER (if applicable)

CODE 7. ADMINISTERED BY

2. AMENDMENT/MODIFICATION NUMBER

CODE

6. ISSUED BY

8. NAME AND ADDRESS OF CONTRACTOR

4. REQUISITION/PURCHASE REQ. NUMBER 3. EFFECTIVE DATE

9A. AMENDMENT OF SOLICITATION NUMBER

9B. DATED

PAGE OF PAGES

10A. MODIFICATION OF CONTRACT/ORDER NUMBER

10B. DATED

BPA NO. 1. CONTRACT ID CODE

FACILITY CODE CODE

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:

The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers

E. IMPORTANT:

is extended,

(a) By completing Items 8 and 15, and returning __________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY is not extended.

12. ACCOUNTING AND APPROPRIATION DATA

(REV. 11/2016)

is required to sign this document and return ___________ copies to the issuing office. is not, A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

15C. DATE SIGNED

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D. OTHER

Contractor

16C. DATE SIGNED

14. DESCRIPTION OF AMENDMENT/MODIFICATION

16B. UNITED STATES OF AMERICA

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER 16A. NAME AND TITLE OF CONTRACTING OFFICER

15B. CONTRACTOR/OFFEROR

STANDARD FORM 30 PREVIOUS EDITION NOT USABLE

Prescribed by GSA - FAR (48 CFR) 53.243

(Type or print) (Type or print)

(Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

(Number, street, county, State and ZIP Code)

(If other than Item 6)

(Specify type of modification and authority)

(such as changes in paying office, appropriation date, etc.)

(If required)

(SEE ITEM 11)

(SEE ITEM 13)

(X)

CHECK

ONE

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

(Signature of person authorized to sign) (Signature of Contracting Officer)

240E

1 10

0001 10-15-2026

00240E

Veterans Health Administration Regional Procurement Office East Building 32 Suite 1A1111 1010 Delafield Road Pittsburgh PA 15215-1802

To all Offerors/Bidders 36C24E26Q0058

X

X X

See CONTINUATION Page

X

1. The purpose of this amendment is publish answers to offeror submitted questions. Please continuation page for all answers.

2. This amendment extends the closing date and time of the solicitation.

Completed quote sheets must be submitted to the Contracting Officer listed below NLT 4:00pm CST, 10/19/2026.

3. Please see continuation page for all items removed from the quote sheet.

Rashaun Thomas Contracting Officer

CONTINUATION PAGE

Attached is a copy of the updated quote sheet. PLEASE KEEP IN MIND ALL INDEX

NUMBERS HAVE CHANGED FROM THE ORGINAL QUOTE SHEET. ALL THE

REMOVED ITEMS INDEX NUMBERS CORRESPOND TO THE ORIGINAL QUOTE

SHEET NOT THE UPDATED QUOTE SHEET.

Index number 56 Original Equipment Manufacture (OEM) part # 47983-BLU is being removed due to Non-TAA compliant status

Does VA intend to apply SBA's Positive Airway Pressure Devices and Supplies Manufacturing class waiver, published at 83 FR 24919, to these two items? Section C.6 refers to a nonmanufacturer-rule waiver, but we did not find a notice identifying one applied to this acquisition. Yes.

Is RFQ 36C24E26Q0058 in fact a small business set aside exclusively? This solicitation is being issued as a tiered evaluation with the following tiers: (1) SDVOSB concerns, (2) VOSB concerns,

(3) small business concerns with HUBZone small business concerns and 8(a) participants having priority, (4) small business concerns and (5) large business concerns. All suppliers are welcome to respond to the RFQ, however the quotes will be evaluated in the tiered hierarchy listed above.

If an item does not receive a fair and reasonable quote from an SBVOSB , all quotes from VOSB will be considered.

Some OEMs have only one or two authorized distributors for their products. In these cases, would a letter from the OEM’s authorized distributor confirming that ABC INC is authorized to purchase and resell the applicable products be acceptable in lieu of a letter issued directly by the OEM? Only Authorized Distributor Letters (ADL) from the Original Equipment Manufacturer (OEM) on OEM’s letterhead will be accepted.

Before submitting a consolidated list of corrections, can you confirm your preferred format for providing feedback? Would you prefer that suppliers submit corrections in the body of an email, provide a separate spreadsheet identifying the affected line items and proposed corrections, or use another format? Please submit all corrected information in an excel spreadsheet or in body of eMail along with all supporting data. Changes will not be made without supporting documentation from the Original Equipment Manufacturer (OEM).

The following index numbers are removed due to Non-TAA compliant status:

INDEX OEM

NUMBER

107 66000317

108 66027640

109 66800834

110 66800276

111 66800279

112 66800836

113 66801067

114 66020044

115 66801306

116 66801307

118 66007630

119 66801068

121 66800452

122 66801304

123 66250707

124 66800835

125 66801069

The statement of work calls for supply to participating prime vendors at an enterprise-wide, nationwide level. ABC INC currently limits its medical-device distribution operations to Texas.

For a particular item we quote, may we limit fulfillment to prime-vendor destinations serving Texas VA facilities, or must we be prepared to supply that item to all participating prime vendors nationwide? Yes, you must be able to supply all prime vendors nationwide.

If nationwide supply is required, would you please clarify whether shipments are generally made to prime-vendor distribution centers, directly to VA facilities when authorized, or both?

Nationwide direct-to-facility and prime-vendor shipping is required.

We would also appreciate guidance on where to find the destinations applicable to a quoted item.

All items need to be available nationwide.

Does the current item list include any skin substitutes, amniotic or placental membrane, collagen, or wound matrix products? No

If our products aren't on this list, is there a process for requesting they be considered in a future MSPV open-market window? Is there a point of contact you'd recommend? Submit the embedded form to vha19plologmspocom@va.gov along with product literature (Provide link directly to product not just company website or PDF).

Product_Sourcing_ Request_6-17-2026.d mailto:vha19plologmspocom@va.gov

Is there a deadline for submitting questions on this solicitation that we should be aware of?

Deadline for question was September 30, 2026.

The solicitation requires offerors to provide documentation demonstrating Electronic Data Interchange (EDI) capability. If an SDVOSB offeror does not currently possess EDI capability or supporting EDI documentation at the time of quote submission, is there any exception, waiver, or alternative method for satisfying this requirement under this solicitation? EDI compliance is mandatory for MSPV participation. There are no exceptions, waivers, or alternative methods for satisfying this requirement.

If an offeror does not currently possess EDI capability, may the offeror satisfy the EDI requirement through a subcontractor, teaming partner, or third-party service provider that has the required EDI capability? Yes, third party service providers are acceptable. If permitted, what documentation should be submitted with the quotation to demonstrate compliance with this requirement? Any documentation from the third-party service showing an agreement between the parties and it outlines the service providers’ capabilities to include emails.

The following index numbers are removed due to being awarded to active BPA:

INDEX OEM NUMBER

186 40711VA

187 50711VA

The following index numbers are removed due to the items being duplicates:

NUMBER

191 CH-14

192 CH-51

67 D1000

We are an SBA-certified SDVOSB interested in quoting these exact products, but we are encountering difficulty obtaining the OEM-signed Authorized Distributor Letters required by the solicitation. Cardinal Health’s Products & Solutions team informed us that it is not accepting additional federal reseller partners at this time and has selected three businesses to represent its products by category. ADL’s are created and signed by the OEM. If the affected items are manufactured by Cardinal Health (Prime vendor) then they (Cardinal) determine the authorized distributors. The SOW does require all MSPV participants to establish EDI compliance with all prime vendors.

Could you confirm whether Uline is the entity expected to sign the OEM letter for part number S18966, and whether an OEM-signed letter naming ABC INC and an authorized wholesaler under Attachment B.1 would satisfy the solicitation if that supply arrangement is available? Uline is the OEM and the only entity authorized to grant ADLs. Only ADLs from the Original Equipment Manufacturer (OEM) on OEM’s letterhead will be accepted.

The following index numbers are removed due to the items being awarded to active contracts or duplicates:

INDEX OEM NUMBER JUSTIFICATION

6 MFA2100-XL

Awarded to active contract

131 GV974HD-BR

Awarded to active contract

132 GV974RD

Awarded to active contract

193 EMP-FBX365HS

Awarded to active contract

202 EMP-FBX365HS Duplicate

Please confirm whether Q4 FY26 is the controlling solicitation-quarter designation and revise Attachment A if the Q3 entry is incorrect. Q4 FY 26 is the current document.

Attachment A appears to repeat identical OEM numbers and supply descriptions for indexes 188/196, 189/197, 190/198, 191/199, 192/200, 193/202, 194/203, and 195/204. Please confirm whether both entries in each pair are intentional. If not, please identify the controlling index and issue a corrected quote sheet. The following index numbers are removed due to the items being awarded to active contracts or duplicates:

INDEX OEM NUMBER JUSTIFICATION

191 CH-14 Duplicate

192 CH-51 Duplicate

193 EMP-FBX365HS

Awarded to active contract 194 14.1205.100 Duplicate

CSA5-250

(7100102603) Duplicate 196 MV0520 Duplicate 197 072228 Duplicate 198 AA031JM Duplicate 202 EMP-FBX365HS Duplicate

Attachment A lists OEM number D1000 at index 67 as a TEGO needle-free hemodialysis connector under ICU Medical Sales Inc. and at index 201 as a needle-free female/male luer-lock connector-adapter under ICU Medical. Please identify the correct OEM name and controlling supply description for OEM number D1000. Index number 67, OEM part number 67 has been removed as it is a duplicate.

Section III.C.3 states that the contractor shall notify the Government within “XX days” if an item moves manufacturing to a non-compliant country. Please replace the placeholder and identify the required notification period for Trade Agreements Act country-of-origin changes. 30 days.

Section III.A.1 references “Appendix C: Veterans Integrated Services Networks (VISNs),” but the RFQ table of contents and VISN listing identify that material as Appendix B. Please confirm Appendix B is the controlling reference and correct Section III.A.1. Appendix B is the controlling reference.

Section I.A.2 directs offerors to Section III.A.4 for Authorized Distributor Letter requirements, while the detailed ADL requirements appear in Section III.A.5. Please confirm Section III.A.5 is the controlling provision and correct the cross-reference. Section III.A.5 is the controlling reference.

The Combined Synopsis/Solicitation Notice describes four evaluation tiers, while RFQ Section E.3 identifies five tiers. Please confirm that the five-tier structure in Section E.3 controls and align the notice and RFQ language. This solicitation is being issued as a tiered evaluation with the following tiers: (1) SDVOSB concerns, (2) VOSB concerns, (3) small business concerns with HUBZone small business concerns and 8(a) participants having priority, (4) small business concerns and (5) large business concerns.

The solicitation materials use “CST,” “CDT,” and “Central Time, Chicago” for the September 30, 2026, comment deadline and October 15, 2026, quotation deadline. Please confirm the controlling deadlines and time-zone convention. Central Standard Time which is abbreviated CST and covers the Chicago area. All abbreviations are acceptable.

Please clarify what documentation the Government will accept as proof of Electronic Data Interchange capability at the time of quotation submission. Any documentation from the third-party service showing an agreement between the parties and it outlines the service providers’ capabilities to include emails. If EDI compliance is being handled internally, documentation from your EDI manager outlining your EDI capabilities and confirmation that EDI has been coordinated with all prime vendors.

Section II.D.1 requires use of “current X12 (EDI) formats” but does not identify the applicable X12 version/release or transaction-specific implementation convention. Please identify the required X12 version/release, or confirm that implementation guides, companion guides, required segment usage, code values, and related mapping requirements will be established by each MSPV Prime Vendor during onboarding. The Authorized Supplier must ensure that data transmission method and format to PVs are through any system that conforms to the current X12 (EDI) formats established by the Accredited Standards Center (ASC) and chartered by the American National Standards Institute (ANSI). The X12 EDI website http://www.x12.org includes additional information on EDI formats.

Please identify the applicable EDI transport requirements, trading-partner identifiers, endpoints, security, or certificate requirements, and required testing or certification. If these requirements vary by MSPV Prime Vendor, please confirm that they will be established individually through the applicable commercial agreement and EDI onboarding process. The Contractor shall report date EDI compliance is established between each prime vendor. The date shall be within 60 days of award. If prime vendor is backlogged for establishing EDI the contractor shall notify the VA and provide monthly updates until compliant. Any requirements for EDI must be clarified by each prime vendor.

Please confirm that the proposal-time proof-of-EDI requirement demonstrates the Offeror’s technical EDI capability and does not require established production connectivity with every MSPV Prime Vendor when the quotation is submitted. Proof-of-ability to fulfill the EDI requirement is required on submission date. The Contractor shall report date EDI compliance is established between each prime vendor. The date shall be within 60 days of award.

OEM name, Index 12–18: "BIOTROL" with OEM numbers 43488x/43489x/434900 (PK Papyrus coronary stent systems). PK Papyrus is marketed by BIOTRONIK. The OEM UEI is blank. Please confirm the OEM name and UEI. Correct OEM: Biotronik INC, and UEI: HYACK54HEMC7

OEM name, Index 1–3: Prevena and SNAP negative-pressure products are listed under "3M_COMPANY." These product lines moved to Solventum, and other lines on the sheet already use Solventum. Please confirm the OEM of record. Solventum US, LLC is the correct OEM.

OEM name, Index 51: Curity adhesive bandage 44102 is listed under Covidien Sales LLC. Please confirm whether the OEM of record should be Cardinal Health. Index number 51 is being removed due non-TAA compliant status.

Inconsistent OEM names: BD vs. BECTON_DICKINSON_AND_COMPANY; CR_BARD vs. C.R.

BARD; OLYMPUS AMERICA vs. OLYMPUS_AMERICA_INC; ICU MEDICAL vs.

ICU_MEDICAL_SALES_INC; SOLVENTUM vs. SOLVENTUM_US,_LLC. The OEM UEI is blank for Ambu, Biotrol, Conmed, Essity, Milliken, Nobel Biocare, Penumbra, Philips and Seirin.

See below for correct OEMs and UEIs:

http://www.x12.org/

NUMBER Correct OEM

N/A PRE1155US.S

SOLVENTUM

US, LLC

92 TFL-FBX200S

OLYMPUS

AMERICA, INC.

188 MV0520

BECTON,

DICKINSON

AND CO

189 072228 CR BARD

199 CH-14 ICU MEDICAL

REVISED UEI OEM

NUMBER OEM

XUNEK78JGC88 DF3116-6121Z AMBU INC.

Z51YLCBWRPU8 N/A Biotrol

FLRKZRGJFXN6 N/A Conmed

L1HLWU1MPWX6 N/A ESSITY

MAS3JT1VNXS4 N/A

MILLIKEN &

COMPANY

MPZPHDXKAHL7 N/A

NOBEL BIO

CARE

QLC9LYKADGX5 N/A PENUMBRA

PWFVQLA9SX78 N/A

PHILIPS

HEALTHCARE

Category: Index 19–22, 24–27 and 29–34 (Boston Scientific Ranger paclitaxel-coated PTA balloons) are categorized as ORTHOPEDICS/PROSTHETICS & SPORTS MEDICINE. These appear to belong in a vascular/cath lab category. Categories have been updated to Laboratory category.

Possible scope issues: Index 8 (Bayer Ra-223 dichloride solution, NDC-format number) appears to be a prescription radiopharmaceutical rather than a medical/surgical supply. Index 186–187

(LogicMark pendants) include monitoring/"lifetime service." Please confirm these are eligible for MSPV. Index numbers 186 and 187 have been removed.

Header: tab "1. Solicitation Information" shows Fiscal Year Quarter "Q3"; the solicitation is Q4 FY26. Correct data is Q4 FY26

Index 8 (Bayer Radium-223 dichloride, NDC 50419-0208-01): this item is a radiopharmaceutical drug product. It may fall outside MSPV scope or be covered by an existing national VA pharmaceutical contract. Item has been removed

ADL date: The Combined Synopsis states the ADL must be signed and dated within 90 days of the Contracting Officer's receipt. SOW Section III.A.5 states within 90 days of the published solicitation date. Please confirm which standard applies. Dated within 90 days of the Contracting Officer's receipt.

The following index numbers are removed due to Non-TAA compliant status:

NUMBER

43 8881412012 44 2556 45 1180600777 51 44102 5 726-15-M-10

The following index numbers are removed due to discontinued status:

NUMBER

135 D12050-B 136 D12120

The following index numbers are being updated to correct DUNS numbers, OEM UEI, and OEM names:

Index OEM Part Number

Revised OEM DUNS Revised OEM UEI Revised OEM NAME

1 PRE1155US.S 102726734 T3QQPHLGT375

KCI USA, Inc. DBA Solventum Advanced

Wound Care

2 SNPA125US.S 102726734 T3QQPHLGT375

KCI USA, Inc. DBA Solventum Advanced

Wound Care

See attached document: S02_Final Quote Sheet_MSPV Q4 FY26 Open Market_36C24E26Q00583_10-7-292611.

3 PRE4001US.S 102726734 T3QQPHLGT375

KCI USA, Inc. DBA Solventum Advanced

Wound Care

181 M8275040/5.S 102726734 T3QQPHLGT375

KCI USA, Inc. DBA Solventum Advanced

Wound Care

183 MA123 102726734 T3QQPHLGT375

KCI USA, Inc. DBA Solventum Advanced

Wound Care